IN2012DN03217A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03217A IN2012DN03217A IN3217DEN2012A IN2012DN03217A IN 2012DN03217 A IN2012DN03217 A IN 2012DN03217A IN 3217DEN2012 A IN3217DEN2012 A IN 3217DEN2012A IN 2012DN03217 A IN2012DN03217 A IN 2012DN03217A
- Authority
- IN
- India
- Prior art keywords
- compounds
- compositions containing
- kinase
- pain
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24310409P | 2009-09-16 | 2009-09-16 | |
| PCT/US2010/049113 WO2011035019A1 (en) | 2009-09-16 | 2010-09-16 | Novel tricyclic protein kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03217A true IN2012DN03217A (enExample) | 2015-10-23 |
Family
ID=43757156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3217DEN2012 IN2012DN03217A (enExample) | 2009-09-16 | 2010-09-16 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110071136A1 (enExample) |
| EP (1) | EP2477493A1 (enExample) |
| JP (1) | JP2013505252A (enExample) |
| KR (1) | KR20120104180A (enExample) |
| CN (1) | CN102647904A (enExample) |
| AU (1) | AU2010295619A1 (enExample) |
| BR (1) | BR112012005970A2 (enExample) |
| CA (1) | CA2774266A1 (enExample) |
| IL (1) | IL218631A0 (enExample) |
| IN (1) | IN2012DN03217A (enExample) |
| MX (1) | MX2012003322A (enExample) |
| SG (1) | SG179163A1 (enExample) |
| WO (1) | WO2011035019A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9342304B2 (en) | 2008-08-15 | 2016-05-17 | Apple Inc. | Processing vectors using wrapping increment and decrement instructions in the macroscalar architecture |
| US8583904B2 (en) | 2008-08-15 | 2013-11-12 | Apple Inc. | Processing vectors using wrapping negation instructions in the macroscalar architecture |
| US9335980B2 (en) | 2008-08-15 | 2016-05-10 | Apple Inc. | Processing vectors using wrapping propagate instructions in the macroscalar architecture |
| US9335997B2 (en) | 2008-08-15 | 2016-05-10 | Apple Inc. | Processing vectors using a wrapping rotate previous instruction in the macroscalar architecture |
| WO2013082292A1 (en) * | 2011-11-29 | 2013-06-06 | Baylor College Of Medicine | A method to enhance cognition |
| US9389860B2 (en) | 2012-04-02 | 2016-07-12 | Apple Inc. | Prediction optimizations for Macroscalar vector partitioning loops |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| US9817663B2 (en) | 2013-03-19 | 2017-11-14 | Apple Inc. | Enhanced Macroscalar predicate operations |
| US9348589B2 (en) | 2013-03-19 | 2016-05-24 | Apple Inc. | Enhanced predicate registers having predicates corresponding to element widths |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CN110279872A (zh) * | 2014-11-11 | 2019-09-27 | 杭州多禧生物科技有限公司 | 细胞毒素分子同细胞结合受体分子的共轭体 |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| SG10202100916PA (en) | 2015-02-02 | 2021-02-25 | Valo Early Discovery Inc | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| CA2975277A1 (en) | 2015-03-04 | 2016-09-09 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors of melk and methods of use |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| JP6798494B2 (ja) * | 2015-07-27 | 2020-12-09 | 味の素株式会社 | システイン誘導体及びシステインスルホキシド誘導体の製造方法 |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| CN111278414A (zh) | 2017-06-06 | 2020-06-12 | 维里卡制药有限公司 | 皮肤病的治疗 |
| WO2018232277A1 (en) | 2017-06-15 | 2018-12-20 | Verrica Pharmaceuticals, Inc. | Devices and methods for the treatment of body surface disorders |
| WO2019028059A1 (en) * | 2017-07-31 | 2019-02-07 | The Regents Of The University Of California | ANTICANCER COMPOUNDS / ANTI-FIBROSIS |
| CA3078325A1 (en) | 2017-10-04 | 2019-04-11 | Verrica Pharmaceuticals Inc. | Synthesis of cantharidin |
| CN109761902B (zh) * | 2017-11-09 | 2022-06-10 | 四川大学 | 6-菲啶酮衍生物及其制备方法和用途 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| BR112021007283A2 (pt) * | 2018-10-19 | 2021-07-20 | Senhwa Biosciences, Inc. | método de tratamento de um câncer ou câncer refratário |
| CN109369528B (zh) * | 2018-11-26 | 2022-03-04 | 天津医科大学 | 三氟甲基取代环戊酮并喹啉化合物及药学上可接受的盐、其制备方法及应用 |
| KR20230004550A (ko) * | 2020-03-30 | 2023-01-06 | 센화 바이오사이언시즈 인코포레이티드 | 간친화성 바이러스 감염증, 특히, 간염 b 및 간염 d를 치료하기 위한 항바이러스성 화합물 및 방법 |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CN113004294B (zh) * | 2021-03-08 | 2023-01-17 | 温州大学新材料与产业技术研究院 | 一种四氢呋喃并1,4-二氢喹啉类化合物及其制备方法和应用 |
| KR20240087788A (ko) | 2021-10-01 | 2024-06-19 | 뉴베일런트, 아이엔씨. | 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조 |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
| PT4355749T (pt) | 2022-04-28 | 2025-08-13 | Xinthera Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| CN115819436B (zh) * | 2022-11-03 | 2023-09-05 | 淮阴师范学院 | 喹啉并环丁砜衍生物的制备方法 |
| CN116947879B (zh) * | 2023-07-25 | 2025-10-31 | 沈阳药科大学 | 一种bbi608类衍生物及其制备方法和在制备治疗stat3介导疾病的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028624A2 (en) * | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| US7956064B2 (en) * | 2006-09-01 | 2011-06-07 | Cylene Pharmaceuticals, Inc. | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators |
-
2010
- 2010-09-16 BR BR112012005970A patent/BR112012005970A2/pt not_active IP Right Cessation
- 2010-09-16 EP EP10817824A patent/EP2477493A1/en not_active Withdrawn
- 2010-09-16 CA CA2774266A patent/CA2774266A1/en not_active Abandoned
- 2010-09-16 AU AU2010295619A patent/AU2010295619A1/en not_active Abandoned
- 2010-09-16 WO PCT/US2010/049113 patent/WO2011035019A1/en not_active Ceased
- 2010-09-16 US US12/883,688 patent/US20110071136A1/en not_active Abandoned
- 2010-09-16 KR KR1020127009482A patent/KR20120104180A/ko not_active Withdrawn
- 2010-09-16 SG SG2012018453A patent/SG179163A1/en unknown
- 2010-09-16 MX MX2012003322A patent/MX2012003322A/es not_active Application Discontinuation
- 2010-09-16 CN CN2010800499607A patent/CN102647904A/zh active Pending
- 2010-09-16 JP JP2012529900A patent/JP2013505252A/ja active Pending
- 2010-09-16 IN IN3217DEN2012 patent/IN2012DN03217A/en unknown
-
2012
- 2012-03-14 IL IL218631A patent/IL218631A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2477493A1 (en) | 2012-07-25 |
| IL218631A0 (en) | 2012-05-31 |
| SG179163A1 (en) | 2012-05-30 |
| BR112012005970A2 (pt) | 2015-09-08 |
| CA2774266A1 (en) | 2011-03-24 |
| MX2012003322A (es) | 2012-07-23 |
| AU2010295619A1 (en) | 2012-05-10 |
| JP2013505252A (ja) | 2013-02-14 |
| US20110071136A1 (en) | 2011-03-24 |
| KR20120104180A (ko) | 2012-09-20 |
| CN102647904A (zh) | 2012-08-22 |
| WO2011035019A1 (en) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03217A (enExample) | ||
| IN2012DN03213A (enExample) | ||
| IN2012DN03112A (enExample) | ||
| MX2011012369A (es) | Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. | |
| MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MY188363A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MX2015014947A (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| WO2012170827A3 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
| ZA201907613B (en) | Dosage regimes for the administration of an anti-cd19 adc | |
| PH12014501061B1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| TN2017000256A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| MX2016009056A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| EA202190041A1 (ru) | Схемы дозирования для введения adc к cd19 | |
| TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
| WO2015024000A3 (en) | Mitochondrially-targeted electrophilic compounds for cancer treatment |